FGF23 is associated with disease severity and prognosis in chronic heart failure

European Journal of Clinical Investigation

Volumn 44, Issue 12, 2014, Pages 1150-1158

  Poelzl, Gerhard ^a   Trenkler, Christian ^a   Kliebhan, Johannes ^a   Wuertinger, Philipp ^b   Seger, Christoph ^b   Kaser, Susanne ^c   Mayer, Gert ^d   Pirklbauer, Markus ^d   Ulmer, Hanno ^a   Griesmacher, Andrea ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c Clinical Division of General Internal Medicine   (Austria)

^d Division of Nephrology and Hypertensiology   (Austria)

Author keywords

Chronic heart failure; FGF23; Metabolic bone disorders; Prognosis

Indexed keywords

25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ADULT; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODYNAMICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; VITAMIN D;

EID: 84912114890     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12349     Document Type: Article

References (40)

1. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671-8.
2. Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. Eur J Clin Invest 2012;42:153-63.
3. Poelzl G, Ess M, Von der Heidt A, Rudnicki M, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance. Eur J Int Med 2013;24:177-82.
4. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
5. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82:737-47.
6. Baum M, Schiavi S, Dwarakanath V, Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 2005;68:1148-53.
7. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;114:S34-42.
8. Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005;9:331-5.
9. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006;21:1187-96.
10. Collins MT, Lindsay JR, Jain A, Kelly MH, Cutler CM, Weinstein LS et al. Fibroblast growth factor-23 is regulated by 1alpha, 25-dihydroxyvitamin D. J Bone Miner Res 2005;20:1944-50.
11. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-9.
12. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8.
13. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl J Med 2008;359:584-92.
14. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009;24:2792-6.
15. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-9.
16. Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-52.
17. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-408.
18. Seiler S, Cremers B, Rebling NM, Hornof F, Jeken J, Kersting S et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011;32:2688-96.
19. Shibata K, Fujita SI, Morita H, Okamoto Y, Sohmiya K, Hoshiga M et al. Correction: association between circulating fibroblast growth factor 23, alpha-klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS ONE 2013;8:e73184.
20. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60:200-7.
21. Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012;42:649-56.
22. Gruson D, Lepoutre T, Ketelslegers JM, Cumps J, Ahn SA, Rousseau MF. C-terminal FGF23 is a strong predictor of survival in systolic heart failure. Peptides 2012;37:258-62.
23. Poss J, Mahfoud F, Seiler S, Heine GH, Fliser D, Bohm M et al. FGF-23 is associated with increased disease severity and early mortality in cardiogenic shock. Eur Heart J Acute Cardiovasc Care 2013;2:211-8.
24. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008;10:321-7.
25. Gotsman I, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. Eur J Heart Fail 2012;14:357-66.
26. Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK et al. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail 2011;13:619-25.
27. Hagstrom E, Ingelsson E, Sundstrom J, Hellman P, Larsson TE, Berglund L et al. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail 2010;12:1186-92.
28. Schierbeck LL, Jensen TS, Bang U, Jensen G, Kober L, Jensen JE. Parathyroid hormone and vitamin D-markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011;13:626-32.
29. Ess M, Heitmair-Wietzorrek K, Frick M, Umlauf N, Ulmer H, Poelzl G. Serum phosphate and long-term outcome among patients with stable heart failure. J Card Fail 2013;19:25-30.
30. Bergwitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 2010;61:91-104.
31. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010;25:993-7.
32. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010;77:292-8.
33. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-8.
34. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 2011;79:234-40.
35. Isakova T, Wolf MS. FGF23 or PTH: which comes first in CKD? Kidney Int 2010;78:947-9.
36. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol 2011;22:1603-9.
37. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69:531-7.
38. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006;104:23-32.
39. Koiwa F, Onoda N, Kato H, Tokumoto A, Okada T, Fukagawa M et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6.
40. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. J Am Soc Nephrol 2010;5:110-6.